FOGHORN THERAPEUTICS I

Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting

14 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting

09 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update

08 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors

27 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program

26 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit

20 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference

27 Sep 2022 08:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

01 Sep 2022 16:05:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Change to Board of Directors

31 Aug 2022 16:05:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS

23 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Appoints Lynne Parshall to its Board of Directors

17 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update

09 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Upcoming Investor Conference Participation

31 May 2022 16:05:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS

19 May 2022 16:01:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides First Quarter 2022 Corporate Update

09 May 2022 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Presents New Preclinical Data on Novel BRG1/BRM Inhibitor FHD-286 at the 2022 AACR Annual Meeting

13 Apr 2022 11:30:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Present Preclinical Data For FHD-286 at the 2022 AACR Annual Meeting

01 Apr 2022 08:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day

11 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook

10 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate at the Cowen’s 42nd Annual Health Care Conference

28 Feb 2022 16:05:01 By Nasdaq GlobeNewswire